title: Metabotropic glutamate receptor subtype mGluR1alpha stimulates the secretion of the amyloid beta-protein precursor ectodomain.
abstract: To examine the effects of glutamatergic neurotransmission on amyloid processing, we stably expressed the metabotropic glutamate receptor subtype 1alpha (mGlu-R1alpha) in HEK 293 cells. Both glutamate and the selective metabotropic agonist 1-amino-1,3-cyclopentanedicarboxylic acid (ACPD) rapidly increased phosphatidylinositol (PI) turnover four- to fivefold compared with control cells that were transfected with the expression vector alone. Increased PI turnover was effectively blocked by the metabotropic antagonist alpha-methyl-4-carbophenylglycine (MCPG), indicating that heterologous expression of mGluR1alpha resulted in efficient coupling of the receptors to G protein and phospholipase C activation. Stimulation of mGluR1alpha with glutamate, quisqualate, or ACPD rapidly increased secretion of the APP ectodomain (APPs); these effects were blocked by MCPG. The metabotropic receptors were coupled to APP processing by protein kinases and by phospholipase A2 (PLA2), and melittin, a peptide that stimulates PLA2, potently increased APPs secretion. These data indicate that mGluR1alpha can be involved in the regulation of APP processing. Together with previous findings that muscarinic and serotonergic receptor subtypes can increase the secretion of the APP ectodomain, these observations support the concept that proteolytic processing of APP is under the control of several major neurotransmitters.
authors.affiliation: Center for Molecular Neurobiology, University of Hamburg, Germany.
authors.forename: R M
authors.initials: RM
authors.lastname: Nitsch
authors.forename: A
authors.initials: A
authors.lastname: Deng
authors.forename: R J
authors.initials: RJ
authors.lastname: Wurtman
authors.forename: J H
authors.initials: JH
authors.lastname: Growdon
mesh_terms: D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D001565:Benzoates / Q000494:pharmacology; D002460:Cell Line; D003515:Cycloleucine / Q000031:analogs & derivatives / Q000494:pharmacology; D004789:Enzyme Activation; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000502:physiology; D015870:Gene Expression; D018698:Glutamic Acid / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D008555:Melitten / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D011494:Protein Kinases / Q000378:metabolism; D016318:Quisqualic Acid / Q000494:pharmacology; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D014162:Transfection; D010738:Type C Phospholipases / Q000378:metabolism
chemical_list: D016564:Amyloid beta-Protein Precursor; D001565:Benzoates; D018691:Excitatory Amino Acid Antagonists; D010716:Phosphatidylinositols; D018094:Receptors, Metabotropic Glutamate; D003515:Cycloleucine; C036361:1-amino-1,3-dicarboxycyclopentane; C079694:alpha-methyl-4-carboxyphenylglycine; D008555:Melitten; D018698:Glutamic Acid; D016318:Quisqualic Acid; D011494:Protein Kinases; D010741:Phospholipases A; D054467:Phospholipases A2; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins; D005998:Glycine